Cargando…
Renal Safety of a Tenofovir-Containing First Line Regimen: Experience from an Antiretroviral Cohort in Rural Lesotho
INTRODUCTION: Current guidelines contraindicate TDF use when creatinine clearance (CrCl) falls below 50 ml/min. We report prevalence of abnormal renal function at baseline and factors associated with abnormal renal function from a community cohort in Lesotho. METHODS: We calculated changes in CrCl f...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047584/ https://www.ncbi.nlm.nih.gov/pubmed/21407815 http://dx.doi.org/10.1371/journal.pone.0017609 |
_version_ | 1782199048635154432 |
---|---|
author | Bygrave, Helen Kranzer, Katharina Hilderbrand, Katherine Jouquet, Guillaume Goemaere, Eric Vlahakis, Nathalie Triviño, Laura Makakole, Lipontso Ford, Nathan |
author_facet | Bygrave, Helen Kranzer, Katharina Hilderbrand, Katherine Jouquet, Guillaume Goemaere, Eric Vlahakis, Nathalie Triviño, Laura Makakole, Lipontso Ford, Nathan |
author_sort | Bygrave, Helen |
collection | PubMed |
description | INTRODUCTION: Current guidelines contraindicate TDF use when creatinine clearance (CrCl) falls below 50 ml/min. We report prevalence of abnormal renal function at baseline and factors associated with abnormal renal function from a community cohort in Lesotho. METHODS: We calculated changes in CrCl from baseline for patients initiated on TDF at 6 and 12 months and the proportion of patients initiated on TDF who developed renal impairment. Screening algorithms were developed using risk factors determined by multivariate analysis. RESULTS: Among 933 adults for whom baseline creatinine was available, 176 (18.9%) presented with a baseline CrCl <50 ml/min. Renal function improved during follow-up. 19 patients who developed renal toxicity during follow up remained on TDF; renal function improved (CrCl≥50 ml/min) in all but 3 of these patients. Among 15 patients with a baseline CrCl <50 ml/min were started in error, none developed severe renal impairment. CONCLUSION: In this setting TDF-associated renal toxicity is rare and mainly transient. Further studies to assess TDF safety at lower CrCl thresholds are warranted. |
format | Text |
id | pubmed-3047584 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-30475842011-03-15 Renal Safety of a Tenofovir-Containing First Line Regimen: Experience from an Antiretroviral Cohort in Rural Lesotho Bygrave, Helen Kranzer, Katharina Hilderbrand, Katherine Jouquet, Guillaume Goemaere, Eric Vlahakis, Nathalie Triviño, Laura Makakole, Lipontso Ford, Nathan PLoS One Research Article INTRODUCTION: Current guidelines contraindicate TDF use when creatinine clearance (CrCl) falls below 50 ml/min. We report prevalence of abnormal renal function at baseline and factors associated with abnormal renal function from a community cohort in Lesotho. METHODS: We calculated changes in CrCl from baseline for patients initiated on TDF at 6 and 12 months and the proportion of patients initiated on TDF who developed renal impairment. Screening algorithms were developed using risk factors determined by multivariate analysis. RESULTS: Among 933 adults for whom baseline creatinine was available, 176 (18.9%) presented with a baseline CrCl <50 ml/min. Renal function improved during follow-up. 19 patients who developed renal toxicity during follow up remained on TDF; renal function improved (CrCl≥50 ml/min) in all but 3 of these patients. Among 15 patients with a baseline CrCl <50 ml/min were started in error, none developed severe renal impairment. CONCLUSION: In this setting TDF-associated renal toxicity is rare and mainly transient. Further studies to assess TDF safety at lower CrCl thresholds are warranted. Public Library of Science 2011-03-02 /pmc/articles/PMC3047584/ /pubmed/21407815 http://dx.doi.org/10.1371/journal.pone.0017609 Text en Bygrave et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Bygrave, Helen Kranzer, Katharina Hilderbrand, Katherine Jouquet, Guillaume Goemaere, Eric Vlahakis, Nathalie Triviño, Laura Makakole, Lipontso Ford, Nathan Renal Safety of a Tenofovir-Containing First Line Regimen: Experience from an Antiretroviral Cohort in Rural Lesotho |
title | Renal Safety of a Tenofovir-Containing First Line Regimen: Experience from an Antiretroviral Cohort in Rural Lesotho |
title_full | Renal Safety of a Tenofovir-Containing First Line Regimen: Experience from an Antiretroviral Cohort in Rural Lesotho |
title_fullStr | Renal Safety of a Tenofovir-Containing First Line Regimen: Experience from an Antiretroviral Cohort in Rural Lesotho |
title_full_unstemmed | Renal Safety of a Tenofovir-Containing First Line Regimen: Experience from an Antiretroviral Cohort in Rural Lesotho |
title_short | Renal Safety of a Tenofovir-Containing First Line Regimen: Experience from an Antiretroviral Cohort in Rural Lesotho |
title_sort | renal safety of a tenofovir-containing first line regimen: experience from an antiretroviral cohort in rural lesotho |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047584/ https://www.ncbi.nlm.nih.gov/pubmed/21407815 http://dx.doi.org/10.1371/journal.pone.0017609 |
work_keys_str_mv | AT bygravehelen renalsafetyofatenofovircontainingfirstlineregimenexperiencefromanantiretroviralcohortinrurallesotho AT kranzerkatharina renalsafetyofatenofovircontainingfirstlineregimenexperiencefromanantiretroviralcohortinrurallesotho AT hilderbrandkatherine renalsafetyofatenofovircontainingfirstlineregimenexperiencefromanantiretroviralcohortinrurallesotho AT jouquetguillaume renalsafetyofatenofovircontainingfirstlineregimenexperiencefromanantiretroviralcohortinrurallesotho AT goemaereeric renalsafetyofatenofovircontainingfirstlineregimenexperiencefromanantiretroviralcohortinrurallesotho AT vlahakisnathalie renalsafetyofatenofovircontainingfirstlineregimenexperiencefromanantiretroviralcohortinrurallesotho AT trivinolaura renalsafetyofatenofovircontainingfirstlineregimenexperiencefromanantiretroviralcohortinrurallesotho AT makakolelipontso renalsafetyofatenofovircontainingfirstlineregimenexperiencefromanantiretroviralcohortinrurallesotho AT fordnathan renalsafetyofatenofovircontainingfirstlineregimenexperiencefromanantiretroviralcohortinrurallesotho |